[Federal Register Volume 70, Number 212 (Thursday, November 3, 2005)]
[Notices]
[Pages 66861-66862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-21897]


=======================================================================
-----------------------------------------------------------------------

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (05-149)]


Notice of Intent To Grant Partially Exclusive License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of intent to grant partially exclusive license.

-----------------------------------------------------------------------

SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(c)(1) 
and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to 
grant a partially exclusive license in the United States to practice 
the inventions described and claimed in U.S. Patent Nos. 5,153,131, 
entitled ``High Aspect Reactor Vessel and Method of Use''; 5,153,132, 
entitled ``Three-Dimensional Co-culture Process''; 5,153,133, entitled 
``Method for Culturing Mammalian Cells in a Horizontally Rotated 
Bioreactor''; 5,155,034, entitled ``Three Dimensional Cell to Tissue 
Assembly Process''; 5,155,035, entitled `` Method for Culturing 
Mammalian Cells in a Perfused Bioreactor''; 5,308,764, entitled 
``Multi-Cellular Three-Dimensional Living Mammalian Tissue''; 
5,496,722, entitled ``Method for Producing Non-neoplastic, Three-
dimensional, Mammalian Tissue and Cell Aggregates under Microgravity 
Culture Conditions

[[Page 66862]]

and the Products Produced Therefrom''; 5,627,021, entitled ``Three-
Dimensional Co-Culture Process''; 5,637,477, entitled ``Recombinant 
Protein Production and Insect Cell Culture and Process''; 5,846,807, 
entitled ``Media Compositions for Three-dimensional Mammalian Tissue 
Grown under Microgravity Culture Conditions''; 5,851,816, entitled 
``Cultured High-Fidelity Three-Dimensional Human Urogenital Tract 
Carcinomas and Process''; 5,858,783, entitled ``Production of Normal 
Mammalian Organ Culture Using a Medium Containing MEM-alpha, Leibovitz 
L-15, Glucose Galactose Fructose''; 5,962,324, entitled ``Three 
Dimensional Optic Tissue Culture and Process''; 6,177,674, entitled 
``Pathogen Propagation in Cultured Three-Dimensional Tissue Mass''; 
6,485,963, entitled ``Growth Stimulation of Biological Cells and Tissue 
by Electromagnetic Fields and Uses Thereof'', 6,673,597, entitled 
``Growth Stimulation of Biological Cells and Tissue by Electromagnetic 
Fields and Uses Thereof''; 6,730,498, entitled ``Production of 
Functional Proteins: Balance of Shear Stress and Gravity''; 6,946,246, 
entitled ``Production of Functional Proteins: Balance of Shear Stress 
and Gravity'', and U.S. Patent Application Serial Number 10/734,759, 
entitled ``Production of Functional Proteins: Balance of Shear Stress 
and Gravity'', U.S. Patent Application Serial Number 10/947,786, 
entitled ``Production of Functional Proteins: Balance of Shear Stress 
and Gravity'', to Renautus Bio Therapeutics, LLC, having its principal 
place of business in Baton Rouge, LA. The patent rights in the 
inventions have been assigned to the United States of America as 
represented by the Administrator of the National Aeronautics and Space 
Administration. The prospective partially exclusive license will comply 
with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

DATES: The prospective exclusive license may be granted unless, within 
fifteen (15) days from the date of this published notice, NASA receives 
written objections including evidence and argument that establish that 
the grant of the license would not be consistent with the requirements 
of 35 U.S.C. 209 and 37 CFR 404.7. Competing applications completed and 
received by NASA within fifteen (15) days of the date of this published 
notice will be treated as objections to the grant of the contemplated 
partially exclusive license.
    Objections submitted in response to this notice will not be made 
available to the public for inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

ADDRESSES: Objections relating to the prospective license may be 
submitted to Patent Counsel, Office of Chief Counsel, Johnson Space 
Center, Mail Code AL, 2101 NASA Parkway, Houston, Texas 77058.

FOR FURTHER INFORMATION CONTACT: Kurt G. Hammerle, Patent Attorney, 
NASA Johnson Space Center, Mail Stop AL, Houston, TX 77058-8452, 
Telephone: (281) 483-1001, Facsimile: (281) 483-6936. Information about 
other NASA inventions available for licensing can be found online at 
http://technology.nasa.gov/.

    Dated: October 26, 2005.
Keith T. Sefton,
Deputy General Counsel, Administration and Management.
[FR Doc. 05-21897 Filed 11-2-05; 8:45 am]
BILLING CODE 7510-13-P